Emergency Management of Bleeding Disorders

National Hemophilia Foundation MASAC Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/1206765

Contents of this Issue


Page 7 of 7

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2019 All rights reserved Disclaimer is pocket guide attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. is pocket guide should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. NHFBLE19123b Drugs Agent Dose a Desmopressin ≥0.3 mcg/kg subcutaneously or else intravenously in 30 mL normal saline over 30 minutes Desmopressin nasal spray "Stimate ® " 1 spray in one nostril for individuals <50 kg 1 spray in each nostril for individuals >50 kg Factor VIII ≥50 units/kg Recombinant factor VIIa (rFVIIa) ≥90 mcg/kg Factor IX 100–120 units/kg Activated prothrombin complex concentrates (FEIBA) ≥75–100 units/kg a Dose should produce a factor level of 80%–100%. Highest doses are for severe bleeding. Abbreviations CAT, computerized axial tomography; PT, prothrombin time; PTT, partial thromboplastin time Source National Hemophilia Foundation. Guidelines for Emergency Department Management of Individuals With Hemophilia and Other Bleeding Disorders. Available at: https://www. hemophilia.org/sites/default/files/document/files/257.pdf.

Articles in this issue

Links on this page

view archives of NHF GUIDELINES Bundle - Emergency Management of Bleeding Disorders